Fusion Pharmaceuticals Inc.

Canada


 
Quantité totale PI 82
Rang # Quantité totale PI 16 194
Note d'activité PI 2,8/5.0    97
Rang # Activité PI 7 142
Symbole boursier FUSN (nasdaq)
ISIN CA36118A1003
Capitalisation 1,800M  (USD)
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

21 4
15 4
35 1
2
 
Dernier brevet 2024 - Use of radiopharmaceuticals for ...
Premier brevet 2016 - Methods, compositions, and kits ...
Dernière marque 2021 - Fusion Pharmaceuticals Inc.
Première marque 2018 - Fast-Clear

Industrie (Classification de Nice)

Derniers inventions, produits et services

2024 Invention Use of radiopharmaceuticals for treatment of cancer. Disclosed are methods of co-administration o...
Invention Claudin 18.2-targeted compounds and uses thereof. Compounds, e.g., radioimmunoconjugates includin...
Invention Psma-targeted radiopharmaceuticals and dna damage response inhibitor combination therapy. Combina...
Invention Extracellular hsp90 (ehsp90)-targeted radiopharmaceuticals and use thereof. Radiopharmaceutical c...
Invention 2,4-dihyroxy-5-isopropylphenyl derivatives and pharmaceutical compositions thereof effective as e...
Invention Steap2-targeted compounds and use thereof. The present disclosure provides compounds or pharmace...
Invention Steap2–targeted compounds and use thereof. The present disclosure provides compounds or pharmaceu...
2023 Invention Combination comprising a neurotensin receptor binding compound and napoli. The present invention...
Invention Combination comprising a neurotensin receptor binding compound and folfirinox. The present inven...
Invention Combination comprising a neurotensin receptor binding compound and napox. The present invention ...
Invention Combination comprising a neurotensin receptor binding compound, gemcitabine and nab-paclitaxel. ...
Invention 2,6-dichlorophenyl ester compounds and use thereof. The present disclosure relates to 2,6-dichlo...
Invention Extracellular hsp90 (ehsp90)-targeted radiopharmaceuticals and use thereof. Conjugates comprising...
Invention Methods of dosing therapeutic agents. MMmaxtranstranstranstrans to reach a desired clinical endpo...
Invention Gucy2c-targeted radiopharmaceuticals and use thereof. Compounds comprising a monocyclic peptide t...
Invention Ntsr1-targeted radiopharmaceuticals and dna damage response inhibitor combination therapy. Method...
Invention Ntsr1-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy. Methods for tre...
Invention Psma-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy. Combination ther...
2022 Invention Egfr-cmet–targeted compounds and uses thereof. Compounds, e.g., radioimmunoconjugates, including ...
Invention Methods of treating cancer. Methods of treatment for conditions, e.g., cancer, using a cold IGF-1...
Invention Claudin 18.2-binding antibodies and fragments thereof. Disclosed herein are antibodies and antibo...
Invention Egfrviii-targeted compounds and uses thereof. Compounds, e.g., radioimmunoconjuguates including a...
Invention Combination comprising a neurotensin receptor binding compound and folfirinox. The present invent...
Invention Combination comprising a neurotensin receptor binding compound and napoli. The present invention ...
Invention Combination comprising a neurotensin receptor binding compound and napox. The present invention r...
Invention Combination comprising a neurotensin receptor binding compound, gemcitabine and nab-paclitaxel. T...
Invention Radioimmunoconjugates and checkpoint inhibitor combination therapy. Combination therapies compri...
Invention Radioimmunoconjugates and checkpoint inhibitor combination therapy. Combination therapies compris...
Invention 2,6-dichlorophenyl ester compounds and use thereof. The present disclosure relates to 2,6-dichlor...
Invention Methods for treatment of cancers. The present disclosure relates to methods of treating a subjec...
Invention Methods for treatment of cancers. The present disclosure relates to methods of treating a subject...
Invention Endosialin-binding antibody. The present disclosure relates to the generation of an antibody tha...
Invention Methods of treating cancer. Methods of treatment for conditions, e.g., cancer, using a cold FGFR...
Invention Use of a cold fgfr3-targeting molecule and a fgfr3 targeting radioimmunoconjugate for treating ca...
2021 P/S Bifunctional chelate material to be used in drug discovery, pharmaceutical development and clinic...
P/S Biopharmaceuticals for the treatment of cancer and other diseases consisting of proteins linked t...
Invention Tem-1-targeted radioimmunoconjugates and uses thereof. Radioimmunoconjugates including a chelatin...
Invention Fgfr3-targeted radioimmunoconjugates and uses thereof. Radioimmunoconjugates including a chelati...
Invention Sustained immunotherapy. Methods of inducing CD8+ T cell infiltration into a tumor in a patient ...
Invention Macrocyclic chelates and uses thereof. The present disclosure relates to macrocyclic chelates in...
2020 Invention Hsp90-binding conjugates and formulations thereof. Conjugates of an active agent attached to a t...
2019 Invention Radioimmunoconjugates and dna damage and repair inhibitor combination therapy. Combination thera...
Invention Actinium-225 and checkpoint inhibitor combination therapy. Combination therapies comprising admin...
P/S Biopharmaceuticals for the treatment of cancer and other diseases consisting of proteins linked ...
2018 P/S Biopharmaceuticals for the treatment of cancer and other diseases consisting of antibodies linked...